Javitt, DC, Zukin, SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301–1308.Google Scholar

Patkar, AA, Mago, R, Masand, PS. Psychotic symptoms in patients with medical disorders. Curr Psychiatry Rep 2004;6:216–224.Google Scholar

Khandaker, GM, Cousins, L, Deakin, J, et al. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry 2015;2:258–270.Google Scholar

Dalmau, J, Tuzun, E, Wu, HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007;61:25–36.Google Scholar

Vitaliani, R, Mason, W, Ances, B, et al. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol 2005;58:594–604.Google Scholar

Florance, NR, Davis, RL, Lam, C, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009;66:11–18.Google Scholar

Dalmau, J, Gleichman, AJ, Hughes, EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7:1091–1098.Google Scholar

Dhossche, D, Fink, M, Shorter, E, Wachtel, LE. Anti-NMDA receptor encephalitis versus pediatric catatonia. Am J Psychiatry 2011;168:749–750.CrossRefGoogle ScholarPubMed

Steiner, J, Walter, M, Glanz, W, et al. Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis. JAMA Psychiatry 2013;70:271–278.Google Scholar

Castillo-Gomez, E, Oliveira, B, Tapken, D, et al. All naturally occurring autoantibodies against the NMDA receptor subunit NR1 have pathogenic potential irrespective of epitope and immunoglobulin class. Mol Psychiatry 2017;22:1776–1784.Google Scholar

Castillo-Gomez, E, Kastner, A, Steiner, J, et al. The brain as immunoprecipitator of serum autoantibodies against N-Methyl-D-aspartate receptor subunit NR1. Ann Neurol 2016;79:144–151.Google Scholar

Zerche, M, Weissenborn, K, Ott, C, et al. Preexisting serum autoantibodies against the NMDAR subunit NR1 modulate evolution of lesion size in acute ischemic stroke. Stroke 2015;46:1180–1186.Google Scholar

Dahm, L, Ott, C, Steiner, J, et al. Seroprevalence of autoantibodies against brain antigens in health and disease. Ann Neurol 2014;76:82–94.Google Scholar

Ehrenreich, H, Steiner, J. Serum autoantibodies against N-methyl-D-aspartate receptor subunit NR1 are no disease indicator. Ann Neurol 2014;31:306–312.Google Scholar

Hammer, C, Stepniak, B, Schneider, A, et al. Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood–brain barrier integrity. Mol Psychiatry 2014;19:1143–1149.Google Scholar

Sperber, PS, Siegerink, B, Huo, S, et al. Serum Anti-NMDA (N-methyl-D-aspartate)-receptor antibodies and long-term clinical outcome after stroke (PROSCIS-B). Stroke 2019;50:3213–3219.Google Scholar

Zandi, MS, Irani, SR, Lang, B, et al. Disease-relevant autoantibodies in first episode schizophrenia. J Neurol 2011;258:686–688.Google Scholar

Tsutsui, K, Kanbayashi, T, Tanaka, K, et al. Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features. BMC Psychiatry 2012;12:37.CrossRefGoogle ScholarPubMed

Zandi, MS, Paterson, RW, Ellul, MA, et al. Clinical relevance of serum antibodies to extracellular N-methyl-D-aspartate receptor epitopes. J Neurol Neurosurg Psychiatry 2015;86:708–713.CrossRefGoogle ScholarPubMed

Hara, M, Martinez-Hernandez, E, Arino, H, et al. Clinical and pathogenic significance of IgG, IgA, and IgM antibodies against the NMDA receptor. Neurology 2018;90:e1386–e1394.CrossRefGoogle ScholarPubMed

Steiner, J, Teegen, B, Schiltz, K, et al. Prevalence of N-methyl-D-aspartate receptor autoantibodies in the peripheral blood: healthy control samples revisited. JAMA Psychiatry 2014;71:838–839.CrossRefGoogle ScholarPubMed

Doss, S, Wandinger, KP, Hyman, BT, et al. High prevalence of NMDA receptor IgA/IgM antibodies in different dementia types. Ann Clin Transl Neurol 2014;1:822–832.Google Scholar

Lancaster, E, Leypoldt, F, Titulaer, MJ, et al. Immunoglobulin G antibodies to the N-methyl-D-aspartate receptor are distinct from immunoglobulin A and immunoglobulin M responses. Ann Neurol 2015;77:183.CrossRefGoogle Scholar

Titulaer, MJ, Dalmau, J. Antibodies to NMDA receptor, blood–brain barrier disruption and schizophrenia: a theory with unproven links. Mol Psychiatry 2014;19:1054.CrossRefGoogle ScholarPubMed

Mane-Damas, M, Hoffmann, C, Zong, S, et al. Autoimmunity in psychotic disorders. Where we stand, challenges and opportunities. Autoimmun Rev 2019;18:102348.Google Scholar

Deakin, J, Lennox, BR, Zandi, MS. Antibodies to the N-methyl-D-aspartate receptor and other synaptic proteins in psychosis. Biol Psychiatry 2014;75:284–291.Google Scholar

Pollak, TA, McCormack, R, Peakman, M, Nicholson, TR, David, AS. Prevalence of anti-N-methyl-d-aspartate (NMDA) antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysis. Psychol Med 2013;44:2475–2487.Google Scholar

Al-Diwani, A, Handel, A, Townsend, L, et al. The psychopathology of NMDAR-antibody encephalitis in adults: a systematic review and phenotypic analysis of individual patient data. Lancet Psychiatry 2019;6:235–246.Google Scholar

Sarkis, RA, Coffey, MJ, Cooper, JJ, Hassan, I, Lennox, B. Anti-N-methyl-D-aspartate receptor encephalitis: a review of psychiatric phenotypes and management considerations – a report of the American Neuropsychiatric Association Committee on Research. J Neuropsychiatry Clin Neurosci 2019;31:137–142.Google Scholar

Warren, N, Siskind, D, O’Gorman, C. Refining the psychiatric syndrome of anti-N-methyl-d-aspartate receptor encephalitis. Acta Psychiatr Scand 2018;138:401–408.Google Scholar

Olney, JW, Farber, NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995;52:998–1007.Google Scholar

Kehrer, C, Maziashvili, N, Dugladze, T, Gloveli, T. Altered excitatory-inhibitory balance in the NMDA-hypofunction model of schizophrenia. Front Mol Neurosci 2008;1:6.Google Scholar

Masdeu, JC, Dalmau, J, Berman, KF. NMDA receptor internalization by autoantibodies: a reversible mechanism underlying psychosis? Trends Neurosci 2016;39:300–310.CrossRefGoogle ScholarPubMed

Gunduz-Bruce, H. The acute effects of NMDA antagonism: from the rodent to the human brain. Brain Res Rev 2009;60:279–286.Google Scholar

Endres, D, Perlov, E, Baumgartner, A, et al. Immunological findings in psychotic syndromes: a tertiary care hospital’s CSF sample of 180 patients. Front Hum Neurosci 2015;9:476.Google Scholar

Oviedo-Salcedo, T, de Witte, L, Kumpfel, T, et al. Absence of cerebrospinal fluid antineuronal antibodies in schizophrenia spectrum disorders. Br J Psychiatry 2018;212:318–320.Google Scholar

Lennox, BR, Palmer-Cooper, EC, Pollak, T, et al. Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis: a case–control study. Lancet Psychiatry 2017;4:42–48.Google Scholar

Kelleher, E, McNamara, P, Dunne, J, et al. Prevalence of N-methyl-D-aspartate receptor antibody (NMDAR-Ab) encephalitis in patients with first episode psychosis and treatment resistant schizophrenia on clozapine, a population based study. Schizophr Res 2020;222:455–461.Google Scholar

Schou, MB, Saether, SG, Drange, OK, et al. The significance of anti-neuronal antibodies for acute psychiatric disorders: a retrospective case-controlled study. BMC Neurosci 2018;19:68.Google Scholar

Jézéquel, J, Rogemond, V, Pollak, T, et al. Cell- and single molecule-based methods to detect anti-N-methyl-D-aspartate receptor autoantibodies in patients with first-episode psychosis from the OPTiMiSE project. Biol Psychiatry 2017;82:766–772.CrossRefGoogle ScholarPubMed

Hoffmann, C, Zong, S, Mane-Damas, M, et al. Absence of autoantibodies against neuronal surface antigens in sera of patients with psychotic disorders. JAMA Psychiatry 2019;7:322–325.Google Scholar

de Witte, LD, Hoffmann, C, van Mierlo, HC, et al. Absence of N-methyl-D-aspartate receptor IgG autoantibodies in schizophrenia: the importance of cross-validation studies. JAMA Psychiatry 2015;72:731–733.Google Scholar

Masopust, J, Andrys, C, Bazant, J, et al. Anti-NMDA receptor antibodies in patients with a first episode of schizophrenia. Neuropsychiatr Dis Treat 2015;11:619–623.Google ScholarPubMed

Gaughran, F, Lally, J, Beck, K, et al. Brain-relevant antibodies in first-episode psychosis: a matched case-control study. Psychol Med 2018;48:1257–1263.Google Scholar

Pollak, TA, Vincent, A, Iyegbe, C, et al. Relationship between serum NMDA receptor antibodies and response to antipsychotic treatment in first-episode psychosis. Biol Psychiatry 2020;90:9–15.CrossRefGoogle ScholarPubMed

Rhoads, J, Guirgis, H, McKnight, C, Duchemin, AM. Lack of anti-NMDA receptor autoantibodies in the serum of subjects with schizophrenia. Schizophr Res 2011;129:213–214.Google Scholar

Vincent, A, Bien, CG, Irani, SR, Waters, P. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol 2011;10:759–772.Google Scholar

Gresa-Arribas, N, Titulaer, MJ, Torrents, A, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol 2014;13:167–177.Google Scholar

Bien, CG, Bien, CI, Dogan Onugoren, M, et al. Routine diagnostics for neural antibodies, clinical correlates, treatment and functional outcome. J Neurol 2020;267:2101–2114.Google Scholar

Zandi, MS, Deakin, JB, Morris, K, et al. Immunotherapy for patients with acute psychosis and serum N-methyl D-aspartate receptor (NMDAR) antibodies: a description of a treated case series. Schizophr Res 2014;160:193–195.Google Scholar

Pollak, TA, Lennox, BR, Muller, S, et al. Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. Lancet Psychiatry 2020;7:93–108.Google Scholar

Scott, JG, Gillis, D, Swayne, A, Blum, S. Testing for antibodies to N-methyl-d-aspartate receptor and other neuronal cell surface antigens in patients with early psychosis. Aust N Z J Psychiatry 2018;52:727–729.Google Scholar

Graus, F, Titulaer, MJ, Balu, R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016;15:391–404.Google Scholar

Warren, N, Swayne, A, Siskind, D, et al. Serum and CSF Anti-NMDAR antibody testing in psychiatry. J Neuropsychiatry Clin Neurosci 2020;32:154–160.Google Scholar

Herken, J, Pruss, H. Red flags: clinical signs for identifying autoimmune encephalitis in psychiatric patients. Front Psychiatry 2017;8:25.Google Scholar

Irani, SR, Bien, CG, Lang, B. Autoimmune epilepsies. Curr Opin Neurol 2011;24:146–153.Google Scholar

Damato, V, Balint, B, Kienzler, AK, Irani, SR. The clinical features, underlying immunology, and treatment of autoantibody-mediated movement disorders. Mov Disord 2018;33:1376–1389.CrossRefGoogle ScholarPubMed

Dubey, D, Kothapalli, N, McKeon, A, et al. Predictors of neural-specific autoantibodies and immunotherapy response in patients with cognitive dysfunction. J Neuroimmunol 2018;323:62–72.Google Scholar

Dubey, D, Singh, J, Britton, JW, et al. Predictive models in the diagnosis and treatment of autoimmune epilepsy. Epilepsia 2017;58:1181–1189.Google Scholar

Dubey, D, Farzal, Z, Hays, R, Brown, LS, Vernino, S. Evaluation of positive and negative predictors of seizure outcomes among patients with immune-mediated epilepsy: a meta-analysis. Ther Adv Neurol Disord 2016;9:369–377.CrossRefGoogle ScholarPubMed

Moussa, T, Afzal, K, Cooper, J, et al. Pediatric anti-NMDA receptor encephalitis with catatonia: treatment with electroconvulsive therapy. Pediatr Rheumatol Online J 2019;17:8.Google Scholar

Coffey, MJ, Cooper, JJ. Electroconvulsive therapy in anti-N-methyl-D-aspartate receptor encephalitis: a case report and review of the literature. J ECT 2016;32:225–229.Google Scholar

Endres, D, Dersch, R, Hochstuhl, B, et al. Intrathecal thyroid autoantibody synthesis in a subgroup of patients with schizophreniform syndromes. J Neuropsychiatry Clin Neurosci 2017;29:365–374.Google Scholar

Endres, D, Perlov, E, Riering, AN, et al. Steroid-responsive chronic schizophreniform syndrome in the context of mildly increased antithyroid peroxidase antibodies. Front Psychiatry 2017;8:64.Google Scholar

Scott, JG, Gillis, D, Ryan, AE, et al. The prevalence and treatment outcomes of antineuronal antibody-positive patients admitted with first episode of psychosis. BJPsych Open 2018;4:69–74.Google Scholar

Leboyer, M, Berk, M, Yolken, RH, et al. Immuno-psychiatry: an agenda for clinical practice and innovative research. BMC Med 2016;14:173.Google Scholar

Ezeoke, A, Mellor, A, Buckley, P, Miller, B. A systematic, quantitative review of blood autoantibodies in schizophrenia. Schizophr Res 2013;150:245–251.Google Scholar

Lejuste, F, Thomas, L, Picard, G, et al. Neuroleptic intolerance in patients with anti-NMDAR encephalitis. Neurol Neuroimmunol Neuroinflamm 2016;3:e280.Google Scholar

Sansing, LH, Tuzun, E, Ko, MW, et al. A patient with encephalitis associated with NMDA receptor antibodies. Nat Clin Pract Neurol 2007;3:291–296.Google Scholar

Dalmau, J, Armangue, T, Planaguma, J, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol 2019;18:1045–1057.Google Scholar

Matsumoto, T, Matsumoto, K, Kobayashi, T, Kato, S. Electroconvulsive therapy can improve psychotic symptoms in anti-NMDA-receptor encephalitis. Psychiatry Clin Neurosci 2012;66:242–243.Google Scholar

Lai, M, Hughes, EG, Peng, X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009;65:424–434.Google Scholar

Lancaster, E, Lai, M, Peng, X, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 2010;9:67–76.Google Scholar

Masdeu, JC, Gonzalez-Pinto, A, Matute, C, et al. Serum IgG antibodies against the NR1 subunit of the NMDA receptor not detected in schizophrenia. Am J Psychiatry 2012;169:1120–1121.Google Scholar

Jézéquel, J, Johansson, EM, Dupuis, JP, et al. Dynamic disorganization of synaptic NMDA receptors triggered by autoantibodies from psychotic patients. Nat Commun 2017;8:1791.Google Scholar

Aviv, R. The death debate; what does it mean to die? The New Yorker, 5 February 2018.Google Scholar

Lehmann-Facius, H. Über die Liquordiagnose der Schizophrenien. Klinische Wochenschrift 1937;16:1646–1648.Google Scholar

Smith, RS. A comprehensive macrophage-T-lymphocyte theory of schizophrenia. Med Hypotheses 1992;39:248–257.Google Scholar

Stein, M, Miller, AH, Trestman, RL. Depression, the immune system, and health and illness: findings in search of meaning. Arch Gen Psychiatry 1991;48:171–177.Google Scholar

Pariante, CM. Psychoneuroimmunology or immunopsychiatry? Lancet Psychiatry 2015;2:197–199.Google Scholar

Yirmiya, R. Endotoxin produces a depressive-like episode in rats. Brain Res 1996;711:163–174.Google Scholar

Udina, M, Navines, R, Egmond, E, et al. Glucocorticoid receptors, brain-derived neurotrophic factor, serotonin and dopamine neurotransmission are associated with interferon-induced depression. Int J Neuropsychopharmacol 2016;19:pyv135.Google Scholar

Breitbart, W, Rosenfeld, B, Tobias, K, et al. Depression, cytokines, and pancreatic cancer. Psychooncology 2014;23:339–345.Google Scholar

Pawar, DS, Molinaro, JR, Knight, JM, Heinrich, TW. Toxicities of CAR T-cell therapy and the role of the consultation-liaison psychiatrist. Psychosomatics 2019;60:519–523.Google Scholar

Bodro, M, Compta, Y, Llanso, L, Esteller, D, et al. Increased CSF levels of IL-1b, IL-6, and ACE in SARS-CoV-2 associated encephalitis. Neurol Neuroimmunol Neuroimflamm 2020;7:e821.Google Scholar

Brown, AS. The Kraepelinian dichotomy from the perspective of prenatal infectious and immunologic insults. Schizophr Bull 2015;41:786–791.Google Scholar

Danese, A, Pariante, CM, Caspi, A, Taylor, A, Poulton, R. Childhood maltreatment predicts adult inflammation in a life-course study. Proc Natl Acad Sci USA 2007;104:1319–1324.CrossRefGoogle Scholar

Copeland, WE, Wolke, D, Lereya, ST, et al. Childhood bullying involvement predicts low-grade systemic inflammation into adulthood. Proc Natl Acad Sci USA 2014;111:7570–7575.Google Scholar

Miller, BJ, Buckley, P, Seabolt, W, Mellor, A, Kirkpatrick, B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011;70:663–671.Google Scholar

Girgis, RR, Kumar, SS, Brown, AS. The cytokine model of schizophrenia: emerging therapeutic strategies. Biol Psychiatry 2014;75:292–299.CrossRefGoogle ScholarPubMed

Black, C, Miller, BJ. Meta-analysis of cytokines and chemokines in suicidality: distinguishing suicidal versus nonsuicidal patients. Biol Psychiatry 2015;78:28–37.Google Scholar

Berk, M, Williams, LJ, Jacka, FN, et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med 2013;11:200.Google Scholar

Rosenblat, JD, McIntyre, RS. Are medical comorbid conditions of bipolar disorder due to immune dysfunction? Acta Psychiatr Scand 2015;132:180–191.Google Scholar

Jeppesen, R, Benros, ME. Autoimmune diseases and psychotic disorders. Front Psychiatry 2019;10:131.Google Scholar

Benros, ME, Nielsen, PR, Nordentoft, M, et al. Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am J Psychiatry 2011;168:1303–1310.Google Scholar

Benros, ME, Pedersen, MG, Rasmussen, H, et al. A nationwide study on the risk of autoimmune diseases in individuals with a personal or a family history of schizophrenia and related psychosis. Am J Psychiatry 2014;171:218–226.Google Scholar

Chen, SW, Zhong, XS, Jiang, LN, et al. Maternal autoimmune diseases and the risk of autism spectrum disorders in offspring: a systematic review and meta-analysis. Behav Brain Res 2016;296:61–69.Google Scholar

Brimberg, L, Mader, S, Jeganathan, V, et al. Caspr2-reactive antibody cloned from a mother of an ASD child mediates an ASD-like phenotype in mice. Mol Psychiatry 2016;21:1663–1671.Google Scholar

Coutinho, E, Jacobson, L, Pedersen, MG, et al. CASPR2 autoantibodies are raised during pregnancy in mothers of children with mental retardation and disorders of psychological development but not autism. J Neurol Neurosurg Psychiatry 2017;88:718–721.Google Scholar

Atladottir, HO, Thorsen, P, Ostergaard, L, et al. Maternal infection requiring hospitalization during pregnancy and autism spectrum disorders. J Autism Dev Disord 2010;40:1423–1430.Google Scholar

Marder, SR, Cannon, TD. Schizophrenia. N Engl J Med 2019;381:1753–1761.Google Scholar

Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014;511:421–427.Google Scholar

Purcell, SM, Moran, JL, Fromer, M, et al. A polygenic burden of rare disruptive mutations in schizophrenia. Nature 2014;506:185–190.Google Scholar

Sundararajan, T, Manzardo, AM, Butler, MG. Functional analysis of schizophrenia genes using GeneAnalytics program and integrated databases. Gene 2018;641:25–34.Google Scholar

Fromer, M, Pocklington, AJ, Kavanagh, DH, et al. De novo mutations in schizophrenia implicate synaptic networks. Nature 2014;506:179–184.Google Scholar

Butler, MG, McGuire, AB, Masoud, H, Manzardo, AM. Currently recognized genes for schizophrenia: high-resolution chromosome ideogram representation. Am J Med Genet B Neuropsychiatr Genet 2016;171B:181–202.Google Scholar

Tost, H, Alam, T, Meyer-Lindenberg, A. Dopamine and psychosis: theory, pathomechanisms and intermediate phenotypes. Neurosci Biobehav Rev 2010;34:689–700.Google Scholar

Carlsson, A. Biochemical and pharmacological aspects of Parkinsonism. Acta Neurol Scand Suppl 1972;51:11–42.Google Scholar

Yaryura-Tobias, JA, Diamond, B, Merlis, S. The action of L-dopa on schizophrenic patients (a preliminary report). Curr Ther Res Clin Exp 1970;12:528–531.Google Scholar

Kim, JS, Kornhuber, HH, Schmid-Burgk, W, Holzmuller, B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 1980;20:379–382.Google Scholar

Krystal, JH, Karper, LP, Seibyl, JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51:199–214.Google Scholar

Kayser, MS, Titulaer, MJ, Gresa-Arribas, N, Dalmau, J. Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-d-aspartate receptor encephalitis. JAMA Neurol 2013;70:1133–1139.Google Scholar

Martucci, L, Wong, AH, De Luca, V, et al. N-methyl-D-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: polymorphisms and mRNA levels. Schizophr Res 2006;84:214–221.Google Scholar

Javitt, DC. Neurophysiological models for new treatment development in schizophrenia: early sensory approaches. Ann N Y Acad Sci 2015;1344:92–104.Google Scholar

Lewis, DA, Hashimoto, T, Volk, DW. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 2005;6:312–324.Google Scholar

Naatanen, R, Kahkonen, S. Central auditory dysfunction in schizophrenia as revealed by the mismatch negativity (MMN) and its magnetic equivalent MMNm: a review. Int J Neuropsychopharmacol 2009;12:125–135.Google Scholar

Lisman, JE, Pi, HJ, Zhang, Y, Otmakhova, NA. A thalamo-hippocampal-ventral tegmental area loop may produce the positive feedback that underlies the psychotic break in schizophrenia. Biol Psychiatry 2010;68:17–24.Google Scholar

Anticevic, A, Gancsos, M, Murray, JD, et al. NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia. Proc Natl Acad Sci USA 2012;109:16720–16725.Google Scholar

Pilowsky, LS, Bressan, RA, Stone, JM, et al. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol Psychiatry 2006;11:118–119.Google Scholar

Poels, EM, Kegeles, LS, Kantrowitz, JT, et al. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol Psychiatry 2014;19:20–29.Google Scholar

Weickert, CS, Fung, SJ, Catts, VS, et al. Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia. Mol Psychiatry 2013;18:1185–1192.Google Scholar

Law, AJ, Deakin, JF. Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neuroreport 2001;12:2971–2974.Google Scholar

Mohn, AR, Gainetdinov, RR, Caron, MG, Koller, BH. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999;98:427–436.Google Scholar

Papaleo, F, Lipska, BK, Weinberger, DR. Mouse models of genetic effects on cognition: relevance to schizophrenia. Neuropharmacology 2012;62:1204–1220.Google Scholar

Moghaddam, B, Javitt, D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2012;37:4–15.Google Scholar

Manto, M, Dalmau, J, Didelot, A, Rogemond, V, Honnorat, J. In vivo effects of antibodies from patients with anti-NMDA receptor encephalitis: further evidence of synaptic glutamatergic dysfunction. Orphanet J Rare Dis 2010;5:31.Google Scholar

Dalmau, J. NMDA receptor encephalitis and other antibody-mediated disorders of the synapse: The 2016 Cotzias Lecture. Neurology 2016;87:2471–2482.Google Scholar

Planaguma, J, Leypoldt, F, Mannara, F, et al. Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. Brain 2015;138:94–109.Google Scholar

Haussleiter, IS, Emons, B, Schaub, M, et al. Investigation of antibodies against synaptic proteins in a cross-sectional cohort of psychotic patients. Schizophr Res 2012;140:258–259.Google Scholar

Chen, CH, Cheng, MC, Liu, CM, et al. Seroprevalence survey of selective anti-neuronal autoantibodies in patients with first-episode schizophrenia and chronic schizophrenia. Schizophr Res 2017;190:28–31.Google Scholar

Endres, D, Meixensberger, S, Dersch, R, et al. Cerebrospinal fluid, antineuronal autoantibody, EEG, and MRI findings from 992 patients with schizophreniform and affective psychosis. Transl Psychiatry 2020;10:279.Google Scholar

Saether, SG, Schou, M, Kondziella, D. What is the significance of onconeural antibodies for psychiatric symptomatology? A systematic review. BMC Psychiatry 2017;17:161.Google Scholar

Saether, SG, Schou, M, Stoecker, W, et al. Onconeural antibodies in acute psychiatric inpatient care. J Neuropsychiatry Clin Neurosci 2017;29:74–76.Google Scholar

Guasp, M, Gine-Serven, E, Rosa-Justicia, M, et al. Clinical, neuro-immunological, and CSF investigations in first episode psychosis. Neurology 2021;97:e61–e75.Google Scholar

Pathmanandavel, K, Starling, J, Merheb, V, et al. Antibodies to surface dopamine-2 receptor and N-methyl-D-aspartate receptor in the first episode of acute psychosis in children. Biol Psychiatry 2015;77:537–547.Google Scholar

Mantere, O, Saarela, M, Kieseppa, T, et al. Anti-neuronal anti-bodies in patients with early psychosis. Schizophr Res 2018;192:404–407.Google Scholar

Engen, K, Wortinger, LA, Jorgensen, KN, et al. Autoantibodies to the N-methyl-D-aspartate receptor in adolescents with early onset psychosis and healthy controls. Front Psychiatry 2020;11:666.Google Scholar

Titulaer, MJ, McCracken, L, Gabilondo, I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013;12:157–165.Google Scholar

van Sonderen, A, Petit-Pedrol, M, Dalmau, J, Titulaer, MJ. The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis. Nat Rev Neurol 2017;13:290–301.Google Scholar

Tobin, WO, Lennon, VA, Komorowski, L, et al. DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. Neurology 2014;83:1797–1803.Google Scholar

Arino, H, Armangue, T, Petit-Pedrol, M, et al. Anti-LGI1-associated cognitive impairment: presentation and long-term outcome. Neurology 2016;87:759–765.Google Scholar

Spatola, M, Sabater, L, Planaguma, J, et al. Encephalitis with mGluR5 antibodies: symptoms and antibody effects. Neurology 2018;90:e1964–e1972.Google Scholar

Graus, F, Boronat, A, Xifro, X, et al. The expanding clinical profile of anti-AMPA receptor encephalitis. Neurology 2010;74:857–859.Google Scholar

Boronat, A, Gelfand, JM, Gresa-Arribas, N, et al. Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol 2013;73:120–128.Google Scholar

Petit-Pedrol, M, Armangue, T, Peng, X, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014;13:276–286.Google Scholar

Sonderen, AV, Arends, S, Tavy, DLJ, et al. Predictive value of electroencephalography in anti-NMDA receptor encephalitis. J Neurol Neurosurg Psychiatry 2018;89:1101–1106.Google Scholar

Armangue, T, Spatola, M, Vlagea, A, et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol 2018;17:760–772.Google Scholar

Dalmau, J, Graus, F. Antibody-mediated encephalitis. N Engl J Med 2018;378:840–851.Google Scholar

Hansen, HC, Klingbeil, C, Dalmau, J, et al. Persistent intrathecal antibody synthesis 15 years after recovering from anti-N-methyl-D-aspartate receptor encephalitis. JAMA Neurol 2013;70:117–119.Google Scholar

Swedo, SE, Leonard, HL, Garvey, M, et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry 1998;155:264–271.Google Scholar

Swedo, SE, Rapoport, JL, Leonard, H, Lenane, M, Cheslow, D. Obsessive-compulsive disorder in children and adolescents: clinical phenomenology of 70 consecutive cases. Arch Gen Psychiatry 1989;46:335–341.Google Scholar

Swedo, SE, Rapoport, JL, Cheslow, DL, et al. High prevalence of obsessive-compulsive symptoms in patients with Sydenham’s chorea. Am J Psychiatry 1989;146:246–249.Google Scholar

Swedo, SE, Leonard, HL, Schapiro, MB, et al. Sydenham’s chorea: physical and psychological symptoms of St Vitus dance. Pediatrics 1993;91:706–713.Google Scholar

Swedo, SE. Sydenham’s chorea: a model for childhood autoimmune neuropsychiatric disorders. JAMA 1994;272:1788–1791.Google Scholar

Rettew, DC, Swedo, SE, Leonard, HL, Lenane, MC, Rapoport, JL. Obsessions and compulsions across time in 79 children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1992;31:1050–1056.Google Scholar

Leonard, HL, Lenane, MC, Swedo, SE, et al. Tics and Tourette’s disorder: a 2- to 7-year follow-up of 54 obsessive-compulsive children. Am J Psychiatry 1992;149:1244–1251.Google Scholar

Swedo, SE, Leonard, HL, Kiessling, LS. Speculations on antineuronal antibody-mediated neuropsychiatric disorders of childhood. Pediatrics 1994;93:323–326.Google Scholar

Chang, K, Frankovich, J, Cooperstock, M, et al. Clinical evaluation of youth with pediatric acute-onset neuropsychiatric syndrome (PANS): recommendations from the 2013 PANS Consensus Conference. J Child Adolesc Psychopharmacol 2015;25:3–13.Google Scholar

Swedo, SE, Leckman, JF, Rose, NR. From research subgroup to clinical syndrome: modifying the PANDAS criteria to describe PANS (pediatric acute-onset neuropsychiatric syndrome). Pediatr Ther 2012;2:2.Google Scholar

Wilbur, C, Bitnun, A, Kronenberg, S, et al. PANDAS/PANS in childhood: controversies and evidence. Paediatr Child Health 2019;24:85–91.Google Scholar

Singer, HS, Gilbert, DL, Wolf, DS, Mink, JW, Kurlan, R. Moving from PANDAS to CANS. J Pediatr 2012;160:725–731.Google Scholar

Allen, AJ, Leonard, HL, Swedo, SE. Case study: a new infection-triggered, autoimmune subtype of pediatric OCD and Tourette’s syndrome. J Am Acad Child Adolesc Psychiatry 1995;34:307–311.Google Scholar

Hesselmark, E, Bejerot, S. Clinical features of paediatric acute-onset neuropsychiatric syndrome: findings from a case–control study. BJPsych Open 2019;5:e25.Google Scholar

Hesselmark, E, Bejerot, S. Biomarkers for diagnosis of Pediatric Acute Neuropsychiatric Syndrome (PANS): sensitivity and specificity of the Cunningham Panel. J Neuroimmunol 2017;312:31–37.Google Scholar

Silverman, M, Frankovich, J, Nguyen, E, et al. Psychotic symptoms in youth with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) may reflect syndrome severity and heterogeneity. J Psychiatr Res 2019;110:93–102.Google Scholar

Bernstein, GA, Victor, AM, Pipal, AJ, Williams, KA. Comparison of clinical characteristics of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and childhood obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2010;20:333–340.Google Scholar

Giedd, JN, Rapoport, JL, Garvey, MA, Perlmutter, S, Swedo, SE. MRI assessment of children with obsessive-compulsive disorder or tics associated with streptococcal infection. Am J Psychiatry 2000;157:281–283.Google Scholar

Cunningham, MW. Rheumatic fever, autoimmunity, and molecular mimicry: the streptococcal connection. Int Rev Immunol 2014;33:314–329.Google Scholar

Shimasaki, C, Frye, RE, Trifiletti, R, et al. Evaluation of the Cunningham Panel in pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS): changes in antineuronal antibody titers parallel changes in patient symptoms. J Neuroimmunol 2020;339:577138.Google Scholar

Kirvan, CA, Swedo, SE, Heuser, JS, Cunningham, MW. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nat Med 2003;9:914–920.Google Scholar

Sigra, S, Hesselmark, E, Bejerot, S. Treatment of PANDAS and PANS: a systematic review. Neurosci Biobehav Rev 2018;86:51–65.Google Scholar

Brown, KD, Farmer, C, Freeman, GM Jr, et al. Effect of early and prophylactic nonsteroidal anti-inflammatory drugs on flare duration in pediatric acute-onset neuropsychiatric syndrome: an observational study of patients followed by an academic community-based pediatric acute-onset neuropsychiatric syndrome clinic. J Child Adolesc Psychopharmacol 2017;27:619–628.Google Scholar

Murphy, TK, Storch, EA, Lewin, AB, Edge, PJ, Goodman, WK. Clinical factors associated with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. J Pediatr 2012;160:314–319.Google Scholar

Armangue, T, Titulaer, MJ, Malaga, I, et al. Pediatric anti-N-methyl-D-aspartate receptor encephalitis: clinical analysis and novel findings in a series of 20 patients. J Pediatr 2013;162:850–856.Google Scholar

Mohammad, SS, Jones, H, Hong, M, et al. Symptomatic treatment of children with anti-NMDAR encephalitis. Dev Med Child Neurol 2016;58:376–384.Google Scholar

Spatola, M, Petit-Pedrol, M, Simabukuro, MM, et al. Investigations in GABAA receptor antibody-associated encephalitis. Neurology 2017;88:1012–1020.Google Scholar

Armangue, T, Olive-Cirera, G, Martinez-Hernandez, E, et al. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurol 2020;19:234–246.Google Scholar

Schiess, N, Pardo, CA. Hashimoto’s encephalopathy. Ann N Y Acad Sci 2008;1142:254–265.Google Scholar

Hollowell, JG, Staehling, NW, Flanders, WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002;87:489–499.Google Scholar

Mattozzi, S, Sabater, L, Escudero, D, et al. Hashimoto encephalopathy in the 21st century. Neurology 2020;94:e217–e224.Google Scholar

Tiosano, S, Nir, Z, Gendelman, O, et al. The association between systemic lupus erythematosus and bipolar disorder: a big data analysis. Eur Psychiatry 2017;43:116–119.Google Scholar

Tiosano, S, Farhi, A, Watad, A, et al. Schizophrenia among patients with systemic lupus erythematosus: population-based cross-sectional study. Epidemiol Psychiatr Sci 2017;26:424–429.Google Scholar

American College of Rheumatology. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599–608.Google Scholar

Ainiala, H, Hietaharju, A, Loukkola, J, et al. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum 2001;45:419–423.Google Scholar

Petri, M, Orbai, AM, Alarcon, GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677–2686.Google Scholar

Appenzeller, S, Cendes, F, Costallat, LT. Acute psychosis in systemic lupus erythematosus. Rheumatol Int 2008;28:237–243.Google Scholar

Pego-Reigosa, JM, Isenberg, DA. Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease. Rheumatology (Oxford) 2008;47:1498–1502.Google Scholar

Hanly, JG, Li, Q, Su, L, et al. Psychosis in systemic lupus erythematosus: results from an international inception cohort study. Arthritis Rheumatol 2019;71:281–289.Google Scholar

Khajezadeh, MA, Zamani, G, Moazzami, B, et al. Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus. Neurol Res Int 2018;2018:2548142.Google Scholar

Sibbitt, WL Jr, Brandt, JR, Johnson, CR, et al. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol 2002;29:1536–1542.Google Scholar

Tay, SH, Mak, A. Comment on: Diagnosing and attributing neuropsychiatric events to systemic lupus erythematosus: time to untie the Gordian Knot?: Reply. Rheumatology (Oxford) 2017;56:857–859.Google Scholar

Hanly, JG, Su, L, Urowitz, MB, et al. Mood disorders in systemic lupus erythematosus: results from an international inception cohort study. Arthritis Rheumatol 2015;67:1837–1847.Google Scholar

Tay, SH, Cheung, PP, Mak, A. Active disease is independently associated with more severe anxiety rather than depressive symptoms in patients with systemic lupus erythematosus. Lupus 2015;24:1392–1399.Google Scholar

Sherer, Y, Gorstein, A, Fritzler, MJ, Shoenfeld, Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 2004;34:501–537.Google Scholar

Zandman-Goddard, G, Chapman, J, Shoenfeld, Y. Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum 2007;36:297–315.Google Scholar

Hanly, JG, Urowitz, MB, Su, L, et al. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis 2011;70:1726–1732.Google Scholar

Press, J, Palayew, K, Laxer, RM, et al. Antiribosomal P antibodies in pediatric patients with systemic lupus erythematosus and psychosis. Arthritis Rheum 1996;39:671–676.Google Scholar

Sciascia, S, Bertolaccini, ML, Roccatello, D, Khamashta, MA, Sanna, G. Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: a systematic review. J Neurol 2014;261:1706–1714.Google Scholar

Gaburo, N Jr, de Carvalho, JF, Timo-Iaria, CIM, et al. Electrophysiological dysfunction induced by anti-ribosomal P protein antibodies injection into the lateral ventricle of the rat brain. Lupus 2017;26:463–469.Google Scholar

Huerta, PT, Kowal, C, DeGiorgio, LA, Volpe, BT, Diamond, B. Immunity and behavior: antibodies alter emotion. Proc Natl Acad Sci USA 2006;103:678–683.Google Scholar

Tin, SK, Xu, Q, Thumboo, J, et al. Novel brain reactive autoantibodies: prevalence in systemic lupus erythematosus and association with psychoses and seizures. J Neuroimmunol 2005;169:153–160.Google Scholar

Varley, JA, Andersson, M, Grant, E, et al. Absence of neuronal autoantibodies in neuropsychiatric systemic lupus erythematosus. Ann Neurol 2020;88:1244–1250.Google Scholar

Haselmann, H, Mannara, F, Werner, C, et al. Human autoantibodies against the AMPA receptor subunit GluA2 induce receptor reorganization and memory dysfunction. Neuron 2018;100:91–105.Google Scholar

Petit-Pedrol, M, Sell, J, Planaguma, J, et al. LGI1 antibodies alter Kv1.1 and AMPA receptors changing synaptic excitability, plasticity and memory. Brain 2018;141:3144–3159.Google Scholar

Carceles-Cordon, M, Mannara, F, Aguilar, E, et al. NMDAR antibodies alter dopamine receptors and cause psychotic behavior in mice. Ann Neurol 2020;88:603–613.Google Scholar

Vitaliani, R, Mason, W, Ances, B, et al. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol 2005;58:594–604.Google Scholar

Dalmau, J, Armangue, T, Planaguma, J, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol 2019;18:1045–1057.Google Scholar

Kayser, MS, Titulaer, MJ, Gresa-Arribas, N, Dalmau, J. Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-D-aspartate receptor encephalitis. JAMA Neurol 2013;70:1133–1139.CrossRefGoogle ScholarPubMed

Chapman, MR, Vause, HE. Anti-NMDA receptor encephalitis: diagnosis, psychiatric presentation, and treatment. Am J Psychiatry 2011;168:245–251.CrossRefGoogle ScholarPubMed

Warren, N, Siskind, D, O’Gorman, C. Refining the psychiatric syndrome of anti-N-methyl-D-aspartate receptor encephalitis. Acta Psychiatr Scand 2018;138:401–408.Google Scholar

Sarkis, RA, Coffey, MJ, Cooper, JJ, Hassan, I, Lennox, B. Anti-N-methyl-D-aspartate receptor encephalitis: a review of psychiatric phenotypes and management considerations – a report of the American Neuropsychiatric Association Committee on Research. J Neuropsychiatry Clin Neurosci 2019;31:137–142.Google Scholar

Al-Diwani, A, Handel, A, Townsend, L, et al. The psychopathology of NMDAR-antibody encephalitis in adults: a systematic review and phenotypic analysis of individual patient data. Lancet Psychiatry 2019;6:235–246.Google Scholar

Titulaer, MJ, McCracken, L, Gabilondo, I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013;12:157–165.Google Scholar

Dalmau, J, Gleichman, AJ, Hughes, EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7:1091–1098.Google Scholar

Irani, SR, Bera, K, Waters, P, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010;133:1655–1667.Google Scholar

Viaccoz, A, Desestret, V, Ducray, F, et al. Clinical specificities of adult male patients with NMDA receptor antibodies encephalitis. Neurology 2014;82:556–563.Google Scholar

Florance, NR, Davis, RL, Lam, C, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009;66:11–18.Google Scholar

Armangue, T, Titulaer, MJ, Malaga, I, et al. Pediatric anti-N-methyl-D-aspartate receptor encephalitis: clinical analysis and novel findings in a series of 20 patients. J Pediatr 2013;162:850–856.Google Scholar

Mohammad, SS, Jones, H, Hong, M, et al. Symptomatic treatment of children with anti-NMDAR encephalitis. Dev Med Child Neurol 2016;58:376–384.Google Scholar

Dale, RC, Irani, SR, Brilot, F, et al. N-methyl-D-aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica. Ann Neurol 2009;66:704–709.Google Scholar

Schumacher, LT, Mann, AP, MacKenzie, JG. Agitation management in pediatric males with anti-N-methyl-D-aspartate receptor encephalitis. J Child Adolesc Psychopharmacol 2016;26:939–943.Google Scholar

Florance-Ryan, N, Dalmau, J. Update on anti-N-methyl-D-aspartate receptor encephalitis in children and adolescents. Curr Opin Pediatr 2010;22:739–744.Google Scholar

Lejuste, F, Thomas, L, Picard, G, et al. Neuroleptic intolerance in patients with anti-NMDAR encephalitis. Neurol Neuroimmunol Neuroinflamm 2016;3:e280.Google Scholar

Warren, N, Grote, V, O’Gorman, C, Siskind, D. Electroconvulsive therapy for anti-N-methyl-d-aspartate (NMDA) receptor encephalitis: a systematic review of cases. Brain Stimul 2019;12:329–334.Google Scholar

Ariño, H, Muñoz-Lopetegi, A, Martinez-Hernandez, E, et al. Sleep disorders in anti-NMDAR encephalitis. Neurology 2020;95:e671–e684.Google Scholar

Gibson, LL, Pollak, TA, Blackman, G, et al. The psychiatric phenotype of anti-NMDA receptor encephalitis. J Neuropsychiatry Clin Neurosci 2019;31:70–79.Google Scholar

Gine Serven, E, Boix Quintana, E, Martinez Ramirez, M, et al. Cycloid psychosis as a psychiatric expression of anti-NMDAR encephalitis: a systematic review of case reports accomplished with the authors’ cooperation. Brain Behav 2021;11:e01980.Google Scholar

Perris, C. A study of cycloid psychoses. Acta Psychiatr Scand Suppl 1974;253:1–77.Google Scholar

Brockington, IF, Perris, C, Kendell, RE, Hillier, VE, Wainwright, S. The course and outcome of cycloid psychosis. Psychol Med 1982;12:97–105.Google Scholar

Roliz A, Shah Y, Morse A, et al., Clinical features of paediatric and adult autoimmune encephalitis: A multicenter sample. Eur J Paediatr Neurol. 2021;30:82–87.Google Scholar

Munoz-Lopetegi, A, Graus, F, Dalmau, J, Santamaria, J. Sleep disorders in autoimmune encephalitis. Lancet Neurol 2020;19:1010–1022.Google Scholar

Ochoa, S, Usall, J, Cobo, J, Labad, X, Kulkarni, J. Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review. Schizophr Res Treatment 2012;2012:916198.Google Scholar

Gresa-Arribas, N, Titulaer, MJ, Torrents, A, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol 2014;13:167–177.Google Scholar

Sonderen, AV, Arends, S, Tavy, DLJ, et al. Predictive value of electroencephalography in anti-NMDA receptor encephalitis. J Neurol Neurosurg Psychiatry 2018;89:1101–1106.Google Scholar

Schmitt, SE, Pargeon, K, Frechette, ES, et al. Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 2012;79:1094–1100.Google Scholar

Peer, M, Pruss, H, Ben-Dayan, I, et al. Functional connectivity of large-scale brain networks in patients with anti-NMDA receptor encephalitis: an observational study. Lancet Psychiatry 2017;4:768–774.Google Scholar

Finke, C, Kopp, UA, Pajkert, A, et al. Structural hippocampal damage following anti-N-methyl-D-aspartate receptor encephalitis. Biol Psychiatry 2016;79:727–734.Google Scholar

Phillips, OR, Joshi, SH, Narr, KL, et al. Superficial white matter damage in anti-NMDA receptor encephalitis. J Neurol Neurosurg Psychiatry 2018;89:518–525.Google Scholar

Leypoldt, F, Buchert, R, Kleiter, I, et al. Fluorodeoxyglucose positron emission tomography in anti-N-methyl-D-aspartate receptor encephalitis: distinct pattern of disease. J Neurol Neurosurg Psychiatry 2012;83:681–686.Google Scholar

Probasco, JC, Solnes, L, Nalluri, A, et al. Abnormal brain metabolism on FDG-PET/CT is a common early finding in autoimmune encephalitis. Neurol Neuroimmunol Neuroinflamm 2017;4:e352.Google Scholar

Endres, D, Perlov, E, Stich, O, et al. Hypoglutamatergic state is associated with reduced cerebral glucose metabolism in anti-NMDA receptor encephalitis: a case report. BMC Psychiatry 2015;15:186.Google Scholar

Heresco-Levy, U, Durrant, AR, Ermilov, M, et al. Clinical and electrophysiological effects of D-serine in a schizophrenia patient positive for anti-N-methyl-D-aspartate receptor antibodies. Biol Psychiatry 2015;77:e27–29.Google Scholar

Sansing, LH, Tuzun, E, Ko, MW, et al. A patient with encephalitis associated with NMDA receptor antibodies. Nat Clin Pract Neurol 2007;3:291–296.Google Scholar

Mohammad, SS, Wallace, G, Ramanathan, S, Brilot, F, Dale, RC. Antipsychotic-induced akathisia and neuroleptic malignant syndrome in anti-NMDAR encephalitis. Ann Clin Psychiatry 2014;26:297–298.Google Scholar

Wang, HY, Li, T, Li, XL, et al. Anti-N-methyl-D-aspartate receptor encephalitis mimics neuroleptic malignant syndrome: case report and literature review. Neuropsychiatr Dis Treat 2019;15:773–778.Google Scholar

Berg, A, Byrne, R, Coffey, BJ. Neuroleptic malignant syndrome in a boy with NMDA receptor encephalitis. J Child Adolesc Psychopharmacol 2015;25:368–371.Google Scholar

Kiani, R, Lawden, M, Eames, P, et al. Anti-NMDA-receptor encephalitis presenting with catatonia and neuroleptic malignant syndrome in patients with intellectual disability and autism. BJPsych Bull 2015;39:32–35.Google Scholar

Rozier, M, Morita, D, King, M. Anti-N-methyl-D-aspartate receptor encephalitis: a potential mimic of neuroleptic malignant syndrome. Pediatr Neurol 2016;63:71–72.Google Scholar

Caroff, SN. Phenomenology and management of encephalitis. J Neuropsychiatry Clin Neurosci 2019;31:399.Google Scholar

Sarkis, RA. Risk of Neuroleptic malignant syndrome in encephalitides: response to Caroff. J Neuropsychiatry Clin Neurosci 2019;31:400.Google Scholar

Hughes, EG, Peng, X, Gleichman, AJ, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010;30:5866–5875.Google Scholar

Ladepeche, L, Dupuis, JP, Bouchet, D, et al. Single-molecule imaging of the functional crosstalk between surface NMDA and dopamine D1 receptors. Proc Natl Acad Sci USA 2013;110:18005–18010.Google Scholar

Grea, H, Bouchet, D, Rogemond, V, et al. Human autoantibodies against N-methyl-D-aspartate receptor modestly alter dopamine D1 receptor surface Dynamics. Front Psychiatry 2019;10:670.Google Scholar

Carceles-Cordon, M, Mannara, F, Aguilar, E, et al. NMDAR antibodies alter dopamine receptors and cause psychotic behavior in mice. Ann Neurol 2020;88:603–613.Google Scholar

Kayser, MS, Dalmau, J. Anti-NMDA receptor encephalitis in psychiatry. Curr Psychiatry Rev 2011;7:189–193.Google Scholar

Baizabal-Carvallo, JF, Stocco, A, Muscal, E, Jankovic, J. The spectrum of movement disorders in children with anti-NMDA receptor encephalitis. Mov Disord 2013;28:543–547.Google Scholar

Sunwoo, JS, Jung, DC, Choi, JY, et al. Successful treatment of refractory dyskinesia secondary to anti-N-methyl-D-aspartate receptor encephalitis with electroconvulsive therapy. J ECT 2016;32:e13–14.Google Scholar

Cooper, JJ, Afzal, KI. Safety of electroconvulsive therapy in 2 very young pediatric patients with catatonia related to anti-N-methyl-D-aspartate receptor encephalitis. J ECT 2019;35:216–217.Google Scholar

Moussa, T, Afzal, K, Cooper, J, et al. Pediatric anti-NMDA receptor encephalitis with catatonia: treatment with electroconvulsive therapy. Pediatr Rheumatol Online J 2019;17:8.Google Scholar

Medina, M, Cooper, JJ. Refractory catatonia due to N-methyl-D-aspartate receptor encephalitis responsive to electroconvulsive therapy: the clinical use of the clock drawing test. J ECT 2017;33:223–224.Google Scholar

Matsumoto, T, Matsumoto, K, Kobayashi, T, Kato, S. Electroconvulsive therapy can improve psychotic symptoms in anti-NMDA-receptor encephalitis. Psychiatry Clin Neurosci 2012;66:242–243.Google Scholar

Braakman, HM, Moers-Hornikx, VM, Arts, BM, Hupperts, RM, Nicolai, J. Pearls & oysters: electroconvulsive therapy in anti-NMDA receptor encephalitis. Neurology 2010;75:e44–e46.Google Scholar

Coffey, MJ, Cooper, JJ. Electroconvulsive therapy in anti-N-methyl-D-aspartate receptor encephalitis: a case report and review of the literature. J ECT 2016;32:225–229.Google Scholar

Creten, C, van der Zwaan, S, Blankespoor, RJ, et al. Late onset autism and anti-NMDA-receptor encephalitis. Lancet 2011;378:98.Google Scholar

Gonzalez-Valcarcel, J, Rosenfeld, MR, Dalmau, J. [Differential diagnosis of encephalitis due to anti-NMDA receptor antibodies]. Neurologia 2010;25:409–413.Google Scholar

Dalmau, J, Graus, F, Rosenblum, MK, Posner, JB. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy: a clinical study of 71 patients. Medicine (Baltimore) 1992;71:59–72.Google Scholar

Alamowitch, S, Graus, F, Uchuya, M, et al. Limbic encephalitis and small cell lung cancer. Clinical and immunological features. Brain 1997;120(Pt 6):923–928.Google Scholar

Dalmau, J, Graus, F, Villarejo, A, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004;127:1831–1844.Google Scholar

Yu, Z, Kryzer, TJ, Griesmann, GE, et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001;49:146–154.Google Scholar

Moss, HE, Liu, GT, Dalmau, J. Glazed (vision) and confused. Surv Ophthalmol 2009;55:169–173.Google Scholar

Antoine, JC, Absi, L, Honnorat, J, et al. Antiamphiphysin antibodies are associated with various paraneoplastic neurological syndromes and tumors. Arch Neurol 1999;56:172–177.Google Scholar

Moon, J, Lee, ST, Shin, JW, et al. Non-stiff anti-amphiphysin syndrome: clinical manifestations and outcome after immunotherapy. J Neuroimmunol 2014;274:209–214.Google Scholar

Peterson, K, Rosenblum, MK, Kotanides, H, Posner, JB. Paraneoplastic cerebellar degeneration: I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992;42:1931–1937.Google Scholar

McKeon, A, Tracy, JA, Pittock, SJ, et al. Purkinje cell cytoplasmic autoantibody type 1 accompaniments: the cerebellum and beyond. Arch Neurol 2011;68:1282–1289.Google Scholar

Ances, BM, Vitaliani, R, Taylor, RA, et al. Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain 2005;128:1764–1777.Google Scholar

Hoftberger, R, van Sonderan, A, Leypoldt, F, et al. Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients. Neurology 2015;84:2403–2412.Google Scholar

Hoftberger, R, Titulaer, MJ, Sabater, L, et al. Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology 2013;81:1500–1506.Google Scholar

Lai, M, Huijbers, MG, Lancaster, E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010;9:776–785.Google Scholar

Irani, SR, Alexander, S, Waters, P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain 2010;133:2734–2748.Google Scholar

van Sonderen, A, Arino, H, Petit-Pedrol, M, et al. The clinical spectrum of Caspr2 antibody-associated disease. Neurology 2016;87:521–528.Google Scholar

Spatola, M, Petit-Pedrol, M, Simabukuro, MM, et al. Investigations in GABAA receptor antibody-associated encephalitis. Neurology 2017;88:1012–1020.Google Scholar

Joubert, B, Kerschen, P, Zekeridou, A, et al. Clinical spectrum of encephalitis associated with antibodies against the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor: case series and review of the literature. JAMA Neurol 2015;72:1163–1169.Google Scholar

Lancaster, E, Lai, M, Peng, X, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 2010;9:67–76.Google Scholar

Jeffery, OJ, Lennon, VA, Pittock, SJ, et al. GABAB receptor autoantibody frequency in service serologic evaluation. Neurology 2013;81:882–887.Google Scholar

Arino, H, Armangue, T, Petit-Pedrol, M, et al. Anti-LGI1-associated cognitive impairment: presentation and long-term outcome. Neurology 2016;87:759–765.Google Scholar

Pollak, TA, Moran, N. Emergence of new-onset psychotic disorder following recovery from LGI1 antibody-associated limbic encephalitis. BMJ Case Rep 2017;2017:bcr2016218328.Google Scholar

Somers, KJ, Lennon, VA, Rundell, JR, et al. Psychiatric manifestations of voltage-gated potassium-channel complex autoimmunity. J Neuropsychiatry Clin Neurosci 2011;23:425–433.Google Scholar

Irani, SR, Pettingill, P, Kleopa, KA, et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol 2012;72:241–255.Google Scholar

Spatola, M, Sabater, L, Planaguma, J, et al. Encephalitis with mGluR5 antibodies: symptoms and antibody effects. Neurology 2018;90:e1964–e1972.Google Scholar

Dale, RC, Merheb, V, Pillai, S, et al. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain 2012;135:3453–3468.Google Scholar

Boronat, A, Gelfand, JM, Gresa-Arribas, N, et al. Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol 2013;73:120–128.Google Scholar

Tobin, WO, Lennon, VA, Komorowski, L, et al. DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. Neurology 2014;83:1797–1803.Google Scholar

Hara, M, Arino, H, Petit-Pedrol, M, et al. DPPX antibody-associated encephalitis: main syndrome and antibody effects. Neurology 2017;88:1340–1348.Google Scholar

Petit-Pedrol, M, Armangue, T, Peng, X, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014;13:276–286.Google Scholar

Pettingill, P, Kramer, HB, Coebergh, JA, et al. Antibodies to GABAA receptor alpha1 and gamma2 subunits: clinical and serologic characterization. Neurology 2015;84:1233–1241.Google Scholar

Gresa-Arribas, N, Planaguma, J, Petit-Pedrol, M, et al. Human neurexin-3alpha antibodies associate with encephalitis and alter synapse development. Neurology 2016;86:2235–2242.Google Scholar

Laurido-Soto, O, Brier, MR, Simon, LE, et al. Patient characteristics and outcome associations in AMPA receptor encephalitis. J Neurol 2019;266:450–460.Google Scholar

Armangue, T, Spatola, M, Vlagea, A, et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol 2018;17:760–772.Google Scholar

Mohammad, SS, Sinclair, K, Pillai, S, et al. Herpes simplex encephalitis relapse with chorea is associated with autoantibodies to N-methyl-D-aspartate receptor or dopamine-2 receptor. Mov Disord 2014;29:117–122.Google Scholar

Hacohen, Y, Deiva, K, Pettingill, P, et al. N-methyl-D-aspartate receptor antibodies in post-herpes simplex virus encephalitis neurological relapse. Mov Disord 2014;29:90–96.Google Scholar

Armangue, T, Leypoldt, F, Malaga, I, et al. Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Ann Neurol 2014;75:317–323.Google Scholar

Leypoldt, F, Titulaer, MJ, Aguilar, E, et al. Herpes simplex virus-1 encephalitis can trigger anti-NMDA receptor encephalitis: case report. Neurology 2013;81:1637–1639.Google Scholar

Ma, J, Han, W, Jiang, L. Japanese encephalitis-induced anti-N-methyl-d-aspartate receptor encephalitis: a hospital-based prospective study. Brain Dev 2020;42:179–184.Google Scholar

Tian, M, Li, J, Lei, W, Shu, X. Japanese encephalitis virus-induced anti-N-methyl-D-aspartate receptor encephalitis: a case report and review of literature. Neuropediatrics 2019;50:111–115.Google Scholar

Schabitz, WR, Rogalewski, A, Hagemeister, C, Bien, CG. VZV brainstem encephalitis triggers NMDA receptor immunoreaction. Neurology 2014;83:2309–2311.Google Scholar

Jankovic, J. Movement disorders in 2016: progress in Parkinson disease and other movement disorders. Nat Rev Neurol 2017;13:76–78.Google Scholar

Balint, B, Vincent, A, Meinck, HM, Irani, SR, Bhatia, KP. Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and pathophysiology. Brain 2018;141:13–36.Google Scholar

Dalmau, J, Geis, C, Graus, F. Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system. Physiol Rev 2017;97:839–887.Google Scholar

Baizabal-Carvallo, JF, Jankovic, J. Autoimmune and paraneoplastic movement disorders: an update. J Neurol Sci 2018;385:175–184.Google Scholar

Caviness, JN, Forsyth, PA, Layton, DD, McPhee, TJ. The movement disorder of adult opsoclonus. Mov Disord 1995;10:22–27.Google Scholar

Irani, SR, Michell, AW, Lang, B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 2011;69:892–900.Google Scholar

Hara, M, Arino, H, Petit-Pedrol, M, et al. DPPX antibody-associated encephalitis: main syndrome and antibody effects. Neurology 2017;88:1340–1348.Google Scholar

Gaig, C, Iranzo, A, Cajochen, C, et al. Characterization of the sleep disorder of anti-IgLON5 disease. Sleep 2019;42:zsz133.Google Scholar

Gaig, C, Compta, Y. Neurological profiles beyond the sleep disorder in patients with anti-IgLON5 disease. Curr Opin Neurol 2019;32:493–499.Google Scholar

Dalmau, J, Graus, F, Villarejo, A, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004;127:1831–1844.Google Scholar

Escudero, D, Guasp, M, Arino, H, et al. Antibody-associated CNS syndromes without signs of inflammation in the elderly. Neurology 2017;89:1471–1475.Google Scholar

Ali, F, Wijdicks, EF. Treatment of movement disorder emergencies in autoimmune encephalitis in the neurosciences ICU. Neurocrit Care 2020;32:286–294.Google Scholar

Cardoso, F, Seppi, K, Mair, KJ, Wenning, GK, Poewe, W. Seminar on choreas. Lancet Neurol 2006;5:589–602.Google Scholar

Sanger, TD, Chen, D, Fehlings, DL, et al. Definition and classification of hyperkinetic movements in childhood. Mov Disord 2010;25:1538–1549.Google Scholar

Florance, NR, Davis, RL, Lam, C, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009;66:11–18.Google Scholar

Titulaer, MJ, McCracken, L, Gabilondo, I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013;12:157–165.Google Scholar

Duan, BC, Weng, WC, Lin, KL, et al. Variations of movement disorders in anti-N-methyl-D-aspartate receptor encephalitis: a nationwide study in Taiwan. Medicine (Baltimore) 2016;95:e4365.Google Scholar

Baizabal-Carvallo, JF, Stocco, A, Muscal, E, Jankovic, J. The spectrum of movement disorders in children with anti-NMDA receptor encephalitis. Mov Disord 2013;28:543–547.Google Scholar

Varley, JA, Webb, AJS, Balint, B, et al. The movement disorder associated with NMDAR antibody-encephalitis is complex and characteristic: an expert video-rating study. J Neurol Neurosurg Psychiatry 2019;90:724–726.Google Scholar

Uchino, A, Iizuka, T, Urano, Y, et al. Pseudo-piano playing motions and nocturnal hypoventilation in anti-NMDA receptor encephalitis: response to prompt tumor removal and immunotherapy. Intern Med 2011;50:627–630.Google Scholar

Armangue, T, Spatola, M, Vlagea, A, et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol 2018;17:760–772.Google Scholar

Mohammad, SS, Sinclair, K, Pillai, S, et al. Herpes simplex encephalitis relapse with chorea is associated with autoantibodies to N-methyl-D-aspartate receptor or dopamine-2 receptor. Mov Disord 2014;29:117–122.Google Scholar

Erer Ozbek, S, Yapici, Z, Tuzun, E, et al. A case of hyperkinetic movement disorder associated with LGI1 antibodies. Turkish J Pediatr 2015;57:514–517.Google Scholar

Lopez-Chiriboga, AS, Klein, C, Zekeridou, A, et al. LGI1 and CASPR2 neurological autoimmunity in children. Ann Neurol 2018;84:473–480.Google Scholar

Armangue, T, Titulaer, MJ, Malaga, I, et al. Pediatric anti-N-methyl-D-aspartate receptor encephalitis: clinical analysis and novel findings in a series of 20 patients. J Pediatr 2013;162:850–856.Google Scholar

Dale, RC, Merheb, V, Pillai, S, et al. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain 2012;135:3453–3468.Google Scholar

Dale, RC, Church, AJ, Surtees, RA, et al. Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity. Brain 2004;127:21–33.Google Scholar

Dale, RC, Irani, SR, Brilot, F, et al. N-methyl-D-aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica. Ann Neurol 2009;66:704–709.Google Scholar

Sinmaz, N, Tea, F, Pilli, D, et al. Dopamine-2 receptor extracellular N-terminus regulates receptor surface availability and is the target of human pathogenic antibodies from children with movement and psychiatric disorders. Acta neuropathologica communications 2016;4:126.Google Scholar

Kirvan, CA, Swedo, SE, Kurahara, D, Cunningham, MW. Streptococcal mimicry and antibody-mediated cell signaling in the pathogenesis of Sydenham’s chorea. Autoimmunity 2006;39:21–29.Google Scholar

Cunningham, MW, Cox, CJ. Autoimmunity against dopamine receptors in neuropsychiatric and movement disorders: a review of Sydenham chorea and beyond. Acta physiologica (Oxford, England) 2016;216:90–100.Google Scholar

Cardoso, F. Autoimmune choreas. J Neurol Neurosurg Psychiatry 2017;88:412–417.Google Scholar

Cardoso, F, Eduardo, C, Silva, AP, Mota, CC. Chorea in fifty consecutive patients with rheumatic fever. Mov Disord 1997;12:701–703.Google Scholar

Maia, DP, Teixeira, AL Jr, Quintao Cunningham, MC, Cardoso, F. Obsessive compulsive behavior, hyperactivity, and attention deficit disorder in Sydenham chorea. Neurology 2005;64:1799–1801.Google Scholar

Singer, HS. Autoantibody-associated movement disorders in children: proven and proposed. Semin Pediatr Neurol 2017;24:168–179.Google Scholar

Brilot, F, Merheb, V, Ding, A, Murphy, T, Dale, RC. Antibody binding to neuronal surface in Sydenham chorea, but not in PANDAS or Tourette syndrome. Neurology 2011;76:1508–1513.Google Scholar

Wilbur, C, Bitnun, A, Kronenberg, S, et al. PANDAS/PANS in childhood: Controversies and evidence. Paediatr Child Health 2019;24:85–91.Google Scholar

Weiner, SG, Normandin, PA. Sydenham chorea: a case report and review of the literature. Pediatr Emerg Care 2007;23:20–24.Google Scholar

Elevli, M, Celebi, A, Tombul, T, Gokalp, AS. Cardiac involvement in Sydenham’s chorea: clinical and Doppler echocardiographic findings. Acta Paediatr 1999;88:1074–1077.Google Scholar

Gurkas, E, Karalok, ZS, Taskin, BD, et al. Predictors of recurrence in Sydenham’s chorea: clinical observation from a single center. Brain Dev 2016;38:827–834.Google Scholar

Cardoso, F, Vargas, AP, Oliveira, LD, Guerra, AA, Amaral, SV. Persistent Sydenham’s chorea. Mov Disord 1999;14:805–807.Google Scholar

Korn-Lubetzki, I, Brand, A. Sydenham’s chorea in Jerusalem: still present. Israel Med Assoc J 2004;6:460–462.Google Scholar

Dean, SL, Singer, HS. Treatment of Sydenham’s chorea: a review of the current evidence. Tremor Other Hyperkinet Mov 2017;7:456.Google Scholar

Pena, J, Mora, E, Cardozo, J, Molina, O, Montiel, C. Comparison of the efficacy of carbamazepine, haloperidol and valproic acid in the treatment of children with Sydenham’s chorea: clinical follow-up of 18 patients. Arq Neuropsiquiatr 2002;60:374–377.Google Scholar

Genel, F, Arslanoglu, S, Uran, N, Saylan, B. Sydenham’s chorea: clinical findings and comparison of the efficacies of sodium valproate and carbamazepine regimens. Brain Dev 2002;24:73–76.Google Scholar

Teixeira, AL, Cardoso, F, Maia, DP, Cunningham, MC. Sydenham’s chorea may be a risk factor for drug induced parkinsonism. J Neurol Neurosurg Psychiatry 2003;74:1350–1351.Google Scholar

Paz, JA, Silva, CA, Marques-Dias, MJ. Randomized double-blind study with prednisone in Sydenham’s chorea. Pediatr Neurol 2006;34:264–269.Google Scholar

Garvey, MA, Snider, LA, Leitman, SF, Werden, R, Swedo, SE. Treatment of Sydenham’s chorea with intravenous immunoglobulin, plasma exchange, or prednisone. J Child Neurol 2005;20:424–429.Google Scholar

Husby, G, van de Rijn, I, Zabriskie, JB, Abdin, ZH, Williams, RC Jr. Antibodies reacting with cytoplasm of subthalamic and caudate nuclei neurons in chorea and acute rheumatic fever. J Exp Med 1976;144:1094–1110.Google Scholar

Singer, HS, Loiselle, CR, Lee, O, Garvey, MA, Grus, FH. Anti-basal ganglia antibody abnormalities in Sydenham chorea. J Neuroimmunol 2003;136:154–161.Google Scholar

Kirvan, CA, Swedo, SE, Heuser, JS, Cunningham, MW. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nat Med 2003;9:914–920.Google Scholar

Kirvan, CA, Cox, CJ, Swedo, SE, Cunningham, MW. Tubulin is a neuronal target of autoantibodies in Sydenham’s chorea. J Immunol 2007;178:7412–7421.Google Scholar

Shimasaki, C, Frye, RE, Trifiletti, R, et al. Evaluation of the Cunningham Panel in pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS): changes in antineuronal antibody titers parallel changes in patient symptoms. J Neuroimmunol 2019;339:577138.Google Scholar

Hesselmark, E, Bejerot, S. Biomarkers for diagnosis of Pediatric Acute Neuropsychiatric Syndrome (PANS): sensitivity and specificity of the Cunningham Panel. J Neuroimmunol 2017;312:31–37.Google Scholar

O’Toole, O, Lennon, VA, Ahlskog, JE, et al. Autoimmune chorea in adults. Neurology 2013;80:1133–1144.Google Scholar

Lamby, N, Leypoldt, F, Schulz, JB, Tauber, SC. Atypical presentation of anti-Ma2-associated encephalitis with choreiform movement. Neurol Neuroimmunol Neuroinflamm 2019;6:e557.Google Scholar

Asherson, RA, Derksen, RH, Harris, EN, et al. Chorea in systemic lupus erythematosus and ‘lupus-like’ disease: association with antiphospholipid antibodies. Semin Arthritis Rheumat 1987;16:253–259.Google Scholar

Cervera, R, Piette, JC, Font, J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002;46:1019–1027.Google Scholar

Cervera, R, Asherson, RA, Font, J, et al. Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature. Medicine (Baltimore) 1997;76:203–212.Google Scholar

Reiner, P, Galanaud, D, Leroux, G, et al. Long-term outcome of 32 patients with chorea and systemic lupus erythematosus or antiphospholipid antibodies. Mov Disord 2011;26:2422–2427.Google Scholar

Dale, RC, Yin, K, Ding, A, et al. Antibody binding to neuronal surface in movement disorders associated with lupus and antiphospholipid antibodies. Dev Med Child Neurol 2011;53:522–528.Google Scholar

Vigliani, MC, Honnorat, J, Antoine, JC, et al. Chorea and related movement disorders of paraneoplastic origin: the PNS EuroNetwork experience. J Neurol 2011;258:2058–2068.Google Scholar

Vernino, S, Tuite, P, Adler, CH, et al. Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann Neurol 2002;51:625–630.Google Scholar

Kujawa, KA, Niemi, VR, Tomasi, MA, et al. Ballistic-choreic movements as the presenting feature of renal cancer. Arch Neurol 2001;58:1133–1135.Google Scholar

Sheen, VL, Asimakopoulos, F, Heyman, E, Henderson, G, Feske, SK. Hemichorea as a presentation of recurrent non-Hodgkin’s lymphoma. J Neurol 2002;249:1746–1748.Google Scholar

Kopecky, J, Kubecek, O, Geryk, T, et al. Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report. J Med Case Rep 2018;12:262.Google Scholar